To reduce IOP in your patients with
open-angle glaucoma or ocular hypertension

VYZULTA® had an IOP-lowering effect
of up to 7 to 9 mmHg across all
9 evaluation time points1

6% conjunctival hyperemia reported as
the most common ocular adverse reaction. Other most common ocular adverse reactions included eye irritation (5%), eye pain (4%), and
instillation site pain (2%)1

30-33% IOP reduction from baseline following 3 months of treatment with VYZULTA®1

Demonstrated a tolerable safety profile: Ocular effects comparable to those of the first-line agent latanoprost and no significant systemic effects1

ONE ACTIVE MOLECULE TWO ROUTES

VYZULTA® is thought to lower IOP by increasing outflow of aqueous humor
through both uveoscleral and trabecular meshwork routes1†